Using a drug to target a specific protein to kill lung cancer cells
Official title: Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer
Funded at Medical University of South Carolina · NIH-10978734 · Data updated 2026-11-12
This study is looking at how a drug called FTY720, usually used for multiple sclerosis, might help treat non-small cell lung cancer by targeting a specific protein in cancer cells to help them die off.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $384,227 |
| NIH project number | 1R01CA285926-01A1 |
| Project ID | NIH-10978734 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have not responded to standard treatments.
✕Less likely to help
Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
What this research studies
This research investigates the use of a drug called FTY720, which is typically used for multiple sclerosis, to treat non-small cell lung cancer (NSCLC). The study focuses on how FTY720 can bind to a protein known as cytoplasmic SET, which is often overexpressed in lung cancer cells. By targeting this protein, the drug may activate a tumor suppressor that leads to cancer cell death through a process called necroptosis. The research will involve both laboratory experiments and animal models to assess the effectiveness of this approach.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with non-small cell lung cancer, potentially improving survival rates.
How similar studies have gone: While the use of FTY720 in cancer treatment is a novel approach, preliminary studies have shown promising results in targeting similar pathways in cancer cells.
Where this research is happening
-
Medical University of South Carolina
Charleston, United States Active
Researchers
- Principal investigator: Ogretmen, Besim — Medical University of South Carolina
- Study coordinator: Ogretmen, Besim
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.